Nuevocor
Pioneering novel therapies for untreatable cardiac diseases
29 employees · est. 2021 · Singapore, Singapore
Aro Biotherapeutics is the older company (2018 vs 2021); Aro Biotherapeutics is the larger of the two.
1 signal in the last 90 days
Side-by-Side Comparison
| Metric | Aro Biotherapeutics | Nuevocor |
|---|---|---|
| Founded | ||
| Founded | 2018 older | 2021 |
| Headquarters | ||
| Headquarters | Philadelphia, United States | Singapore, Singapore |
| Employees | ||
| Employees | 51 larger | 29 |
| Industry | ||
| Industry | Biotechnology, Health Care, Health and Wellness | Biopharma, Biotechnology, Pharmaceutical |
| Funding Stage | ||
| Funding Stage | Series B | Series B |
| Total Funding | ||
| Total Funding | $166.50M | $80.60M |
| Funding Rounds | ||
| Funding Rounds | 4 | 3 |
| Services | ||
| Services | Development of Centyrin-based Therapeutic Candidates, Research and Optimization of Receptor-specific Centyrins, Conjugation of Centyrins to Oligonucleotides | Development of novel therapies for cardiomyopathies, Genetic medicine research and development, Mechanobiology-centered treatment approaches |
| Target Customers | ||
| Target Customers | Patients with Genetic Disorders, Biotechnology Industry Partners, Researchers in Genetic Medicine | Patients with untreatable cardiomyopathies, Healthcare providers specializing in cardiology, Research institutions focusing on cardiovascular diseases |
| Taxonomy | ||
| Taxonomy | Genetic Medicines, Tissue-targeted Therapies, Philadelphia, Centyrins, Therapeutic Candidates, Proprietary Protein Technology, Disease Therapies, Drug Development, Biopharmaceuticals, Industry Partnerships, Disease Targeting, Genetic Medicine Innovation | Genetic Medicines, Cardiomyopathies, Gene Therapy, Cardiac Function Restoration, PrOSIA Mechanobiology Platform, Preclinical-stage, Biopharmaceutical Company, Genetic Cardiomyopathies, Novel Therapies, Cardiac Diseases, Disease Treatment |
| Website | ||
| Website | arobiotx.com | nuevocor.com |
About Aro Biotherapeutics
Aro Biotherapeutics, founded in 2018 and headquartered in the United States, is at the forefront of biotechnology innovation. The company specializes in developing tissue-targeted genetic medicines, leveraging its proprietary Centyrins technology. This platform is propelling the creation of a robust...
About Nuevocor
Nuevocor, founded in 2021, is a pioneering company in the Biopharma, Biotechnology, and Pharmaceutical industries. With its headquarters nestled in Singapore and operational reach extending to the USA, Nuevocor is at the forefront of developing genetic medicines targeted at previously untreatable ge...
We will tell you when either one moves
BounceWatch watches Aro Biotherapeutics and Nuevocor for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at Aro Biotherapeutics and Nuevocor — by email.
Frequently Asked Questions
Compare Aro Biotherapeutics with someone else
Start typing a company name or domain.
Compiled from the BounceWatch company index. We last looked at Aro Biotherapeutics on 12 Sep 2024, and Nuevocor on 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
